

## **NOTAGLI:**

**Nosological imaging as a tool for adjusting therapy combination to improve glioma management: preclinical studies**

## **ADRESSED PATHOLOGY:**

Cancer/Gliomas

## **GENERAL OBJECTIVE:**

NOTAGLI uses different preclinical models of brain Glioblastoma (primary and secondary) for validating metabolome-based intermediate surrogate biomarkers of response. Magnetic Resonance Spectroscopic Imaging (MRSI)-based Molecular Imaging (Nosological Imaging) are used for detection of early therapy response and appearance of resistance. The information obtained could be used to make decisions about the therapeutic strategies, which could be different in each case, leading to an individualization of the therapeutic protocol.

## **PARTICIPANTS:**

**Ana Paula Candiota/Carles Arús, UAB**

Jesús Santamaría, UNIZAR

Ibane Abasolo, H. Vall d'Hebron

Andrés Santos, UPC

## **CLINICAL/EXTERNAL GROUPS:**

Alejandro Fernández, H. Bellvitge

Joan Martí Fàbregas, H. Sant Pau

Maria Ruzzene, U. Studi di Padova

Emili Itarte, UAB